Meta Salud Diabetes study protocol: A cluster-randomised trial to reduce cardiovascular risk among a diabetic population of Mexico

Samantha J Sabo, Catalina Denman Champion, Melanie L Bell, Elsa Cornejo Vucovich, Maia Ingram, Celina Valenica, Maria Del Carmen Castro Vasquez, Eduardo Gonzalez-Fagoaga, Jill Geurnsey De Zapien, Cecilia B Rosales

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction Northern Mexico has among the highest rates of cardiovascular disease (CVD) and diabetes in the world. This research addresses core gaps in implementation science to develop, test and scale-up CVD risk-reduction interventions in diabetics through a national primary care health system. Methods and analysis The Meta Salud Diabetes (MSD) research project is a parallel two-arm cluster-randomised clinical behavioural trial based in 22 (n=22) health centres in Sonora, Mexico. MSD aims to evaluate the effectiveness of the MSD intervention for the secondary prevention of CVD risk factors among a diabetic population (n=320) compared with the study control of usual care. The MSD intervention consists of 2-hour class sessions delivered over a 13-week period providing educational information to encourage sustainable behavioural change to prevent disease complications including the adoption of physical activity. MSD is delivered within the context of Mexico's national primary care health centre system by health professionals, including nurses, physicians and community health workers via existing social support groups for individuals diagnosed with chronic disease. Mixed models are used to estimate the effect of MSD by comparing cardiovascular risk, as measured by the Framingham Risk Score, between the trial arms. Secondary outcomes include hypertension, behavioural risk factors and psychosocial factors. Ethics and dissemination This work is supported by the National Institutes of Health, National Heart Lung and Blood Institute (1R01HL125996-01) and approved by the University of Arizona Research Institutional Review Board (Protocol 1508040144) and the Research Bioethics Committee at the University of Sonora. The first Internal Review Board approval date was 31 August 2015 with five subsequent approved amendments. This article refers to protocol V.0.2, dated 30 January 2017. Results will be disseminated via peer-reviewed publication and presentation at international conferences and will be shared through meetings with health systems officials. Trial registration number NCT0280469; Pre-results.

Original languageEnglish (US)
Article numbere020762
JournalBMJ Open
Volume8
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Mexico
Cardiovascular Diseases
Research
Population
Primary Health Care
Health
National Heart, Lung, and Blood Institute (U.S.)
Bioethics
Self-Help Groups
Research Ethics Committees
National Institutes of Health (U.S.)
Risk Reduction Behavior
Secondary Prevention
Ethics
Social Support
Publications
Chronic Disease
Randomized Controlled Trials
Nurses
Exercise

Keywords

  • coronary heart disease
  • general diabetes
  • public health

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Meta Salud Diabetes study protocol : A cluster-randomised trial to reduce cardiovascular risk among a diabetic population of Mexico. / Sabo, Samantha J; Denman Champion, Catalina; Bell, Melanie L; Cornejo Vucovich, Elsa; Ingram, Maia; Valenica, Celina; Del Carmen Castro Vasquez, Maria; Gonzalez-Fagoaga, Eduardo; Geurnsey De Zapien, Jill; Rosales, Cecilia B.

In: BMJ Open, Vol. 8, No. 3, e020762, 01.03.2018.

Research output: Contribution to journalArticle

Sabo, SJ, Denman Champion, C, Bell, ML, Cornejo Vucovich, E, Ingram, M, Valenica, C, Del Carmen Castro Vasquez, M, Gonzalez-Fagoaga, E, Geurnsey De Zapien, J & Rosales, CB 2018, 'Meta Salud Diabetes study protocol: A cluster-randomised trial to reduce cardiovascular risk among a diabetic population of Mexico', BMJ Open, vol. 8, no. 3, e020762. https://doi.org/10.1136/bmjopen-2017-020762
Sabo, Samantha J ; Denman Champion, Catalina ; Bell, Melanie L ; Cornejo Vucovich, Elsa ; Ingram, Maia ; Valenica, Celina ; Del Carmen Castro Vasquez, Maria ; Gonzalez-Fagoaga, Eduardo ; Geurnsey De Zapien, Jill ; Rosales, Cecilia B. / Meta Salud Diabetes study protocol : A cluster-randomised trial to reduce cardiovascular risk among a diabetic population of Mexico. In: BMJ Open. 2018 ; Vol. 8, No. 3.
@article{51169efbe46b435f83fc2a9f21b3f3c2,
title = "Meta Salud Diabetes study protocol: A cluster-randomised trial to reduce cardiovascular risk among a diabetic population of Mexico",
abstract = "Introduction Northern Mexico has among the highest rates of cardiovascular disease (CVD) and diabetes in the world. This research addresses core gaps in implementation science to develop, test and scale-up CVD risk-reduction interventions in diabetics through a national primary care health system. Methods and analysis The Meta Salud Diabetes (MSD) research project is a parallel two-arm cluster-randomised clinical behavioural trial based in 22 (n=22) health centres in Sonora, Mexico. MSD aims to evaluate the effectiveness of the MSD intervention for the secondary prevention of CVD risk factors among a diabetic population (n=320) compared with the study control of usual care. The MSD intervention consists of 2-hour class sessions delivered over a 13-week period providing educational information to encourage sustainable behavioural change to prevent disease complications including the adoption of physical activity. MSD is delivered within the context of Mexico's national primary care health centre system by health professionals, including nurses, physicians and community health workers via existing social support groups for individuals diagnosed with chronic disease. Mixed models are used to estimate the effect of MSD by comparing cardiovascular risk, as measured by the Framingham Risk Score, between the trial arms. Secondary outcomes include hypertension, behavioural risk factors and psychosocial factors. Ethics and dissemination This work is supported by the National Institutes of Health, National Heart Lung and Blood Institute (1R01HL125996-01) and approved by the University of Arizona Research Institutional Review Board (Protocol 1508040144) and the Research Bioethics Committee at the University of Sonora. The first Internal Review Board approval date was 31 August 2015 with five subsequent approved amendments. This article refers to protocol V.0.2, dated 30 January 2017. Results will be disseminated via peer-reviewed publication and presentation at international conferences and will be shared through meetings with health systems officials. Trial registration number NCT0280469; Pre-results.",
keywords = "coronary heart disease, general diabetes, public health",
author = "Sabo, {Samantha J} and {Denman Champion}, Catalina and Bell, {Melanie L} and {Cornejo Vucovich}, Elsa and Maia Ingram and Celina Valenica and {Del Carmen Castro Vasquez}, Maria and Eduardo Gonzalez-Fagoaga and {Geurnsey De Zapien}, Jill and Rosales, {Cecilia B}",
year = "2018",
month = "3",
day = "1",
doi = "10.1136/bmjopen-2017-020762",
language = "English (US)",
volume = "8",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "3",

}

TY - JOUR

T1 - Meta Salud Diabetes study protocol

T2 - A cluster-randomised trial to reduce cardiovascular risk among a diabetic population of Mexico

AU - Sabo, Samantha J

AU - Denman Champion, Catalina

AU - Bell, Melanie L

AU - Cornejo Vucovich, Elsa

AU - Ingram, Maia

AU - Valenica, Celina

AU - Del Carmen Castro Vasquez, Maria

AU - Gonzalez-Fagoaga, Eduardo

AU - Geurnsey De Zapien, Jill

AU - Rosales, Cecilia B

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Introduction Northern Mexico has among the highest rates of cardiovascular disease (CVD) and diabetes in the world. This research addresses core gaps in implementation science to develop, test and scale-up CVD risk-reduction interventions in diabetics through a national primary care health system. Methods and analysis The Meta Salud Diabetes (MSD) research project is a parallel two-arm cluster-randomised clinical behavioural trial based in 22 (n=22) health centres in Sonora, Mexico. MSD aims to evaluate the effectiveness of the MSD intervention for the secondary prevention of CVD risk factors among a diabetic population (n=320) compared with the study control of usual care. The MSD intervention consists of 2-hour class sessions delivered over a 13-week period providing educational information to encourage sustainable behavioural change to prevent disease complications including the adoption of physical activity. MSD is delivered within the context of Mexico's national primary care health centre system by health professionals, including nurses, physicians and community health workers via existing social support groups for individuals diagnosed with chronic disease. Mixed models are used to estimate the effect of MSD by comparing cardiovascular risk, as measured by the Framingham Risk Score, between the trial arms. Secondary outcomes include hypertension, behavioural risk factors and psychosocial factors. Ethics and dissemination This work is supported by the National Institutes of Health, National Heart Lung and Blood Institute (1R01HL125996-01) and approved by the University of Arizona Research Institutional Review Board (Protocol 1508040144) and the Research Bioethics Committee at the University of Sonora. The first Internal Review Board approval date was 31 August 2015 with five subsequent approved amendments. This article refers to protocol V.0.2, dated 30 January 2017. Results will be disseminated via peer-reviewed publication and presentation at international conferences and will be shared through meetings with health systems officials. Trial registration number NCT0280469; Pre-results.

AB - Introduction Northern Mexico has among the highest rates of cardiovascular disease (CVD) and diabetes in the world. This research addresses core gaps in implementation science to develop, test and scale-up CVD risk-reduction interventions in diabetics through a national primary care health system. Methods and analysis The Meta Salud Diabetes (MSD) research project is a parallel two-arm cluster-randomised clinical behavioural trial based in 22 (n=22) health centres in Sonora, Mexico. MSD aims to evaluate the effectiveness of the MSD intervention for the secondary prevention of CVD risk factors among a diabetic population (n=320) compared with the study control of usual care. The MSD intervention consists of 2-hour class sessions delivered over a 13-week period providing educational information to encourage sustainable behavioural change to prevent disease complications including the adoption of physical activity. MSD is delivered within the context of Mexico's national primary care health centre system by health professionals, including nurses, physicians and community health workers via existing social support groups for individuals diagnosed with chronic disease. Mixed models are used to estimate the effect of MSD by comparing cardiovascular risk, as measured by the Framingham Risk Score, between the trial arms. Secondary outcomes include hypertension, behavioural risk factors and psychosocial factors. Ethics and dissemination This work is supported by the National Institutes of Health, National Heart Lung and Blood Institute (1R01HL125996-01) and approved by the University of Arizona Research Institutional Review Board (Protocol 1508040144) and the Research Bioethics Committee at the University of Sonora. The first Internal Review Board approval date was 31 August 2015 with five subsequent approved amendments. This article refers to protocol V.0.2, dated 30 January 2017. Results will be disseminated via peer-reviewed publication and presentation at international conferences and will be shared through meetings with health systems officials. Trial registration number NCT0280469; Pre-results.

KW - coronary heart disease

KW - general diabetes

KW - public health

UR - http://www.scopus.com/inward/record.url?scp=85044179338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044179338&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2017-020762

DO - 10.1136/bmjopen-2017-020762

M3 - Article

C2 - 29530914

AN - SCOPUS:85044179338

VL - 8

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 3

M1 - e020762

ER -